摘要
目的探讨治疗相关急性髓系白血病(t-AML)的发病机制、治疗方法和预后。方法回顾性分析1例乳腺癌化疗后t-AML患者的临床资料、诊疗经过,并结合相关文献进行复习。结果本例患者染色体核型为少见的克隆性异常t(6;11)(q27;q23),MLL-AF6融合基因阳性,应用标准方案化疗后2次复发,至今未缓解。结论t-AML主要与放疗、应用细胞毒药物相关,可应用蒽环类/阿糖胞苷为基础的标准化疗方案、去甲基化及异基因造血干细胞移植等进行治疗,患者预后较差。
Objective To investigate the pathogenesis, treatment, and prognosis of therapy-related acute myeloid leukemia(t-AML). Methods A retrospective analysis was performed for the clinical data and the diagnosis and treatment processes of a patient with t-AML after chemotherapy for breast cancer, and a literature review was also performed. Results The patient in this case had the chromosome karyotype of a rare clonal abnormality, t(6;11)(q27;q23), and positive MLL-AF6 fusion gene. The patient experienced recurrence twice after chemotherapy with standard regimen and did not achieve remission up to now. Conclusion T-AML is mainly associated with radiotherapy and application of cytotoxic drugs and can be treated with anthracycline/cytarabine-based standard chemotherapy, demethylation, and allogeneic hematopoietic stem cell transplantation. T-AML often has a poor prognosis.
作者
张婷
高燕
孟繁军
ZHANG Ting;GAO Yan;MENG Fanjun(Department of Hematology,The Affiliated Hospital of Qingdao University,Qingdao 266003,China)
出处
《精准医学杂志》
2022年第6期515-517,522,共4页
Journal of Precision Medicine
基金
重大疾病防治科技行动计划项目(2018ZX-07S-007)。
关键词
白血病
髓样
急性
治疗学
病因学
预后
基因检测
造血干细胞移植
Leukemia,myeloid,acute
Therapeutics
Etiology
Prognosis
Genetic testing
Hematopoietic stem cell transplantation
